Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Z5OE
|
||||
| Former ID |
DAP000033
|
||||
| Drug Name |
Mitotane
|
||||
| Synonyms |
Chloditan; Chlodithan; Chlodithane; Khloditan; Khlodithan; Lysodren; Mitotan; Mitotano; Mitotanum; Mytotan; Bristol Myers Squibb Brand of Mitotane; C 3010; CB 313; CB313; PS694_SUPELCO; Bristol-Myers Squibb Brand of Mitotane; CB-313; Lysodren (TN); Mitotano [INN-Spanish]; Mitotanum [INN-Latin]; Ortho,para DDD; Mitotane [USAN:INN:JAN]; O,p-DDD; O,p-Tde; Ortho,para-DDD; Mitotane (JAN/USP/INN); O,p'-DDD; O,p'-Dichlorodiphenyldichloroethane; O,p'-TDE; Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)-(8CI); (+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; (2,4'-Dichlorodiphenyl)dichloroethane; (o,p)-DDD; 1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane; 1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane; 1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane; 1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; 1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene; 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene; 2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane; 2,4'-Ddd; 2,4'-Dichlorodiphenyldichloroethane; 2,4'-Dichlorophenyldichlorethane; 2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane; 2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticancer Agents
|
||||
| Company |
Bristol Myers Squibb
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C14H10Cl4
|
||||
| InChI |
InChI=1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
|
||||
| InChIKey |
JWBOIMRXGHLCPP-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 53-19-0
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
94579, 612321, 4440061, 7847486, 7980007, 8136992, 8149962, 8152632, 10321176, 10525583, 11335878, 11361117, 11364915, 11367477, 11370039, 11372116, 11374376, 11378209, 11408080, 11462089, 11484528, 11488732, 11490685, 11492524, 11495773, 14801378, 17389949, 17404814, 24855696, 24861830, 24872530, 24899277, 26613412, 26680209, 26747348, 26747349, 26752984, 29223316, 46508319, 47365201, 47589014, 47736498, 48185011, 48413513, 48421846, 48423858, 48425423, 49854406, 50105583, 50105584
|
||||
| SuperDrug ATC ID |
L01XX23
|
||||
| SuperDrug CAS ID |
cas=000053190
|
||||
| Target and Pathway | |||||
| Target(s) | Estrogen receptor | Target Info | Binder | [536081], [536207] | |
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Signaling events mediated by HDAC Class II | |||||
| Plasma membrane estrogen receptor signaling | |||||
| LKB1 signaling events | |||||
| Regulation of Telomerase | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| FOXM1 transcription factor network | |||||
| Validated nuclear estrogen receptor alpha network | |||||
| Signaling mediated by p38-alpha and p38-beta | |||||
| FOXA1 transcription factor network | |||||
| References | |||||
| Ref 538481 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 016885. | ||||
| Ref 541993 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6957). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.